Home Our Products UthPeak® Reduced NMN (NMNH)

UthPeak® Reduced NMN (NMNH)

World's First, Largest, and Longest Human Clinical Trial on Reduced NMN (NMNH)

Product Name: β-Nicotinamide Mononucleotide, reduced form (Reduced NMN, NMNH)

CAS No. : 3083704-66-6

NCT Number: NCT06889740

Phase I clinical trial results have shown UthPeak^® Reduced NMN (NMNH) effects on

3X NAD+ INCREMENT
5 Years YOUNGER
35% Boost in ENERGY
31% Improvement in EMOTIONAL WELLNESS

UthPeak® has recently obtained the self-affirmed GRAS status for use in selected conventional foods, dietary supplements, and medical foods.

About NMNH

Reduced NMN (NMNH) is the reduced form of Nicotinamide Mononucleotide (NMN). Both NMN and reduced NMN (also known as NMNH) are NAD+ precursors. Research has shown that NMNH is a more effective NAD+ enhancer than market-available NAD+ precursors.

Health Value of NAD+

NAD+ is widely recognized in the scientific community as a key factor in the aging process. As we age, NAD+ levels gradually decline, leading to metabolic changes and increased disease susceptibility. Supplementing NAD+ can effectively delay aging and reduce the risk of age-related diseases. Scientific research has confirmed that increasing NAD+ levels can improve mitochondrial function, repair damaged DNA, and maintain genomic stability. This results in health benefits such as promoting brain, cardiovascular, and liver health, as well as providing anti-inflammatory effects.

More about NAD+ in health

Why UthPeak® NMNH

Preclinical and clinical studies to ensure safety and efficacy

EffePharm has been dedicated to delivering safe and clinically backed ingredients. To ensure the safety of UthPeak^® reduced NMN (also know as NMNH), comprehensive preclinical toxicology studies have been conducted. UthPeak^® is the first reduced NMN brand globally to conduct the largest and longest human clinical trial on reduced NMN.

UthPeak® NMNH Clinical Agenda

UthPeak^® reduced NMN (NMNH) has completed a 90-day Phase I clinical trial with 80 healthy participants, demonstrating promising safety, increased NAD+ levels, and reduced biological age indicators, along with improved emotional well-being and energy support.
The forthcoming phase II UthPeak^® clinical trials in 2025 will concentrate on assessing reduced NMN’s potential to enhance consumer-centric well-being factors such as cardioprotection, neuroprotection, and liver protection.

World's First, Largest, and Longest Human Clinical Studies Results

Phase I clinical trial results have shown UthPeak^® Reduced NMN (NMNH) effects on

3X NAD+ INCREMENT
5 Years YOUGNER
35% Boost in ENERGY
31% Improvement in EMOTIONAL WELLNESS

More About UthPeak® Cinical Trial

Preclinical Studies

The completion of extensive animal studies has underscored the potential of UthPeak^® in various areas of health and wellness.

The ingredient has shown promising results in:

ANTI-FATIGUE
SLEEP QUALITY IMPROVEMENT
CARDIOVASCULAR HEALTH PROMOTION
BRAIN FUNCTION ENHANCEMENT
ANTI-AGING

Keep updated with UthPeak® Reduced NMN studies

Market Insights

According to the United Nations World Population Prospects 2022, the population aged 65 and above is growing more rapidly than the population below that age. This means that the percentage of the global population aged 65 and above is expected to rise from 10% in 2022 to 16% in 2050. The rise of population aging continues to drive the demand for nutritious and healthy foods.

More about UthPeak® Reduced NMN insights

Technology

UthPeak^® is the first Market-Ready Reduced NMN brand.

Patent status: Patent pending crystalline form of Reduced NMN (NMNH)

Superior stability: Improved stability is designed to be compatible with various product formats.

High purity: Purity higher than 98%.

Versatile application: Suitable for powder, tablets, capsules, and other dosage forms.

Marketing Support

Marketing subsidiary program

At EffePharm, we understand the pivotal role marketing plays in driving brand growth and fostering lasting connections with consumers. That’s why we’re thrilled to unveil this unprecedented opportunity for our clients. Partner with EffePharm today and unlock the full power of our market insights to drive smarter decisions and stronger results.

Learn More

More about UthPeak® Reduced NMN

Customer Site

To read more about UthPeak^® Reduced NMN (NMNH), or to find out UthPeak^® Reduced NMN where to buy UthPeak^® Reduced NMN, visit uthpeak.com.

If you are a brand formulating with UthPeak^® Reduced NMN and would like to be featured on our site, please contact us.

More about UthPeak® NMNH

Qualification Assurance

Self-Gras obtained.
Kosher, and halal certified.
Manufactured in IOS9001, cGMP certified facilities.

Frequently Asked Question About UthPeak® NMNH

01 What makes UthPeak® NMNH different from regular NMN supplements?
UthPeak® is made up of reduced NMN (NMNH), which is a compound that differs in structure from NMN, not just a simple variant. Compared to NMN, NMNH is utilizing a different metabolic route—commonly known as the NMNH pathway—that is assumed to facilitate overcoming the usual production bottlenecks of NAD+ in the body. The tentative studies indicate that NMNH might be the body's source of NAD+ that could become a more effective one. In a cited experiment, the level of NAD+ was elevated up to 5 times more than with usual NMN, highlighting UthPeak® as one of the best NMNH supplement products.
02 Is UthPeak® NMNH safe for long-term use?
Yes. UthPeak® has undergone toxicological evaluations and a 90-day human safety study. It has also obtained self-affirmed GRAS status for use in selected conventional foods, dietary supplements, and medical foods. These findings support its suitability as an NMNH supplement for long-term nutritional applications.
03 How does UthPeak® NMNH support anti-aging?
UthPeak® NMNH works by significantly boosting NAD+ levels, which decline with age. This increase—driven by the more efficient NMNH pathway—is linked to improved mitochondrial health, energy production, DNA repair, and reduced biological age, which are key markers of healthy aging.
04 Can UthPeak® NMNH help with emotional and physical energy?
The answer is yes. The UthPeak® NMNH (Reduced NMN) phase I clinical trial showed a 31% improvement in emotional wellness and a 35% increase in energy levels, making this NMNH supplement ideal for those seeking both cognitive clarity and physical vitality.
05 Is UthPeak® available in flexible formulations?
Yes. With high purity (>98%) and improved stability (2–8°C storage), UthPeak® NMNH is designed for diverse applications—powders, tablets, capsules—making it an excellent option for brands developing the best NMNH powder.

UthPeak® – Endorsed by Science, Trusted by Experts

Dr. Richard Kaszynski

Science Consultant

Co-Founder and Director, Stanford Solutions Trustee, the ASHINAGA organization

“Recently, reduced nicotinamide mononucleotide (NMNH) has emerged as a promising NAD+ intermediate, demonstrating significant potential to boost NAD+ levels and support various health benefits. UthPeak® NMNH stands out, validated by positive results from its phase I clinical trial.”

Learn More

Related Products

Our products

Get your
sample

Secure the Science-Backed Edge with UthPeak® Reduced NMN

Be first to market with the future of NAD+ enhancement, high purity NMNH with UthPeak®

Keep updated

Reference available upon request.
The content on this page is for business use only and is not intended for end consumers.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

Information on this site is provided for informational purposes only. It is not meant to substitute for medical advice from your physician or other medical professional. You should not use the information contained herein to diagnose or treat a health problem or disease or prescribe any medication. Carefully read all product documentation. If you have or suspect that you have a medical problem, promptly contact your regular healthcare provider.

UthPeak^® is a registered trademark of EffePharm Ltd.

As the global population ages, consumers are looking for better and safer methods to maintain a long and healthy life. The new and improved UthPeak® NMNH by Effepharm is made with a reduced NMN ingredient and is the first globally, the largest, and the longest human clinical trial on NMNH supplements which back it up, setting the standard.

UthPeak® uses NMNH, the reduced form of NMN, which is different from the traditional NAD+ boosters. That improved composition-specific activation of the NMNH pathway gives the possibility of skipping the slowest steps of NAD+ biosynthesis. Consequently, the levels of NAD⁺ can be raised to thrice, which is the first step for the cell energy, metabolic function, and the renewal of the aging process. The first phase clinical trial participants reported a rejuvenation of five years, giving an energy rise of 35% and emotional wellness’ improvement of 31%.

More than just a supplement, UthPeak® is a science-validated solution. With self-affirmed GRAS status, high purity (>98%), and improved temperature stability (2–8°C), it offers both formulation flexibility and consumer confidence.

For brands looking for the best NMNH powder or seeking to enhance their NAD+ product lines with advanced NMNH supplements, UthPeak® provides exceptional performance, safety, and scientific credibility. Its patent-pending crystalline structure ensures compatibility with capsules, tablets, and functional food formats.

UthPeak® is known as one of the top NMNH supplements that appeal to the new trends of consumers who care about their health and want not only to be promised something but to be helped. Such consumers require NMNH supplements that provide genuine, quantifiable outcomes that stem from a verified NMNH pathway.